SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)
$3.75 -0.08 (-2.0888%)
Analysed SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) News Sources
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
19-03-2026
yahoo.com
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
18-03-2026
yahoo.com
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
17-03-2026
yahoo.com
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
10-03-2026
yahoo.com
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
09-03-2026
yahoo.com
SAB BIO to Participate in Upcoming Investor Conferences
02-03-2026
yahoo.com
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf
01-03-2026
marketbeat.com
SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026
15-02-2026
marketbeat.com
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
25-01-2026
yahoo.com
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
07-01-2026
yahoo.com
What is the current price of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The current price of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is $3.75.
SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) absolute price change since previous trading day?
The absolute price change of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) since the previous trading day is $-0.08.
SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) percentage price change since previous trading day?
The percentage price change of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) since the previous trading day is -2.0888%.
What is the most recent average sentiment score for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The most recent average sentiment score for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The most recent sentiment for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is .
SEC-8K** Filing Available For SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.